Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
Abstract
TO THE EDITOR:
Novel immunotherapies have recently led to a broadened spectrum of therapeutic options in pediatric B-cell precursor acute lymphoblastic leukemia, even in the setting of relapsed/refractory disease. However, antibody therapy for T-cell acute lymphoblastic leukemia (T-ALL)...
Paper Details
Title
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
Published Date
Aug 22, 2019
Journal
Volume
134
Issue
8
Pages
713 - 716
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History